Is CLYM or MDWD more profitable?

Climb Bio has a net margin of 0.00% compared to MediWound's net margin of -180.30%. Climb Bio's return on equity of -31.45% beat MediWound's return on equity. Company Net Margins Return on Equity Return on Assets Climb Bio N/A -31.45% -30.39% MediWound -180.30% -67.22% -31.87%

Does the media prefer CLYM or MDWD?

In the previous week, Climb Bio had 1 more articles in the media than MediWound. MarketBeat recorded 2 mentions for Climb Bio and 1 mentions for MediWound. MediWound's average media sentiment score of 0.00 beat Climb Bio's score of -0.19 indicating that MediWound is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral MediWound 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, MDWD or CRMD?

CorMedix has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MediWound $16.96M 11.49 -$23.88M -$2.26 N/A CorMedix $311.71M 2.20 $163.05M $2.13 4.11

Is MDWD or CRMD more profitable?

CorMedix has a net margin of 45.25% compared to MediWound's net margin of -180.30%. CorMedix's return on equity of 45.57% beat MediWound's return on equity. Company Net Margins Return on Equity Return on Assets MediWound -180.30% -67.22% -31.87% CorMedix 45.25% 45.57% 24.76%

Does the media refer more to MDWD or CRMD?

In the previous week, CorMedix had 1 more articles in the media than MediWound. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for MediWound. CorMedix's average media sentiment score of 0.95 beat MediWound's score of 0.00 indicating that CorMedix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CorMedix 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, OCS or MDWD?

MediWound has higher revenue and earnings than Oculis. MediWound is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oculis $1.45M 564.61 -$119.44M -$2.13 N/A MediWound $16.96M 11.49 -$23.88M -$2.26 N/A

Is OCS or MDWD more profitable?

MediWound has a net margin of -180.30% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat MediWound's return on equity. Company Net Margins Return on Equity Return on Assets Oculis -8,460.67% -56.78% -45.62% MediWound -180.30% -67.22% -31.87%

Does the media refer more to OCS or MDWD?

In the previous week, Oculis had 3 more articles in the media than MediWound. MarketBeat recorded 4 mentions for Oculis and 1 mentions for MediWound. Oculis' average media sentiment score of 1.24 beat MediWound's score of 0.00 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MediWound 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MDWD or ACRS?

In the previous week, MediWound and MediWound both had 1 articles in the media. Aclaris Therapeutics' average media sentiment score of 0.50 beat MediWound's score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aclaris Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MDWD or CADL?

In the previous week, Candel Therapeutics had 8 more articles in the media than MediWound. MarketBeat recorded 9 mentions for Candel Therapeutics and 1 mentions for MediWound. MediWound's average media sentiment score of 0.00 beat Candel Therapeutics' score of -0.07 indicating that MediWound is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MediWound 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Candel Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

MediWound (MDWD) Competitors

$15.16 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$15.18 +0.03 (+0.16%)

As of 07/2/2026 04:04 PM Eastern

Compare

MDWD vs. CLYM, CRMD, OCS, ACRS, and CADL

Should you buy MediWound stock or one of its competitors? MarketBeat compares MediWound with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MediWound include Climb Bio (CLYM), CorMedix (CRMD), Oculis (OCS), Aclaris Therapeutics (ACRS), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry.

How does MediWound compare to Climb Bio?

Climb Bio (NASDAQ:CLYM) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Climb Bio presently has a consensus target price of $21.73, suggesting a potential upside of 68.43%. MediWound has a consensus target price of $34.00, suggesting a potential upside of 124.27%. Given MediWound's higher probable upside, analysts plainly believe MediWound is more favorable than Climb Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Climb Bio	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

69.8% of Climb Bio shares are owned by institutional investors. Comparatively, 46.8% of MediWound shares are owned by institutional investors. 2.6% of Climb Bio shares are owned by company insiders. Comparatively, 9.2% of MediWound shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Climb Bio had 1 more articles in the media than MediWound. MarketBeat recorded 2 mentions for Climb Bio and 1 mentions for MediWound. MediWound's average media sentiment score of 0.00 beat Climb Bio's score of -0.19 indicating that MediWound is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Climb Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Climb Bio has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market. Comparatively, MediWound has a beta of 0.14, suggesting that its stock price is 86% less volatile than the broader market.

MediWound has higher revenue and earnings than Climb Bio. Climb Bio is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Climb Bio	N/A	N/A	-$59.85M	-$0.78	N/A
MediWound	$16.96M	11.49	-$23.88M	-$2.26	N/A

Climb Bio has a net margin of 0.00% compared to MediWound's net margin of -180.30%. Climb Bio's return on equity of -31.45% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Climb Bio	N/A	-31.45%	-30.39%
MediWound	-180.30%	-67.22%	-31.87%

Summary

Climb Bio beats MediWound on 9 of the 16 factors compared between the two stocks.

How does MediWound compare to CorMedix?

MediWound (NASDAQ:MDWD) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk and media sentiment.

CorMedix has a net margin of 45.25% compared to MediWound's net margin of -180.30%. CorMedix's return on equity of 45.57% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-180.30%	-67.22%	-31.87%
CorMedix	45.25%	45.57%	24.76%

MediWound presently has a consensus price target of $34.00, suggesting a potential upside of 124.27%. CorMedix has a consensus price target of $15.00, suggesting a potential upside of 71.43%. Given MediWound's higher probable upside, analysts clearly believe MediWound is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

CorMedix has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	11.49	-$23.88M	-$2.26	N/A
CorMedix	$311.71M	2.20	$163.05M	$2.13	4.11

46.8% of MediWound shares are held by institutional investors. Comparatively, 34.2% of CorMedix shares are held by institutional investors. 9.2% of MediWound shares are held by company insiders. Comparatively, 3.5% of CorMedix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

MediWound has a beta of 0.14, indicating that its stock price is 86% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market.

In the previous week, CorMedix had 1 more articles in the media than MediWound. MarketBeat recorded 2 mentions for CorMedix and 1 mentions for MediWound. CorMedix's average media sentiment score of 0.95 beat MediWound's score of 0.00 indicating that CorMedix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CorMedix	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

CorMedix beats MediWound on 12 of the 16 factors compared between the two stocks.

How does MediWound compare to Oculis?

Oculis (NASDAQ:OCS) and MediWound (NASDAQ:MDWD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

MediWound has a net margin of -180.30% compared to Oculis' net margin of -8,460.67%. Oculis' return on equity of -56.78% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oculis	-8,460.67%	-56.78%	-45.62%
MediWound	-180.30%	-67.22%	-31.87%

Oculis currently has a consensus target price of $38.33, suggesting a potential upside of 171.48%. MediWound has a consensus target price of $34.00, suggesting a potential upside of 124.27%. Given Oculis' stronger consensus rating and higher possible upside, equities analysts plainly believe Oculis is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

22.3% of Oculis shares are held by institutional investors. Comparatively, 46.8% of MediWound shares are held by institutional investors. 9.2% of MediWound shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Oculis has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, MediWound has a beta of 0.14, indicating that its stock price is 86% less volatile than the broader market.

MediWound has higher revenue and earnings than Oculis. MediWound is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oculis	$1.45M	564.61	-$119.44M	-$2.13	N/A
MediWound	$16.96M	11.49	-$23.88M	-$2.26	N/A

In the previous week, Oculis had 3 more articles in the media than MediWound. MarketBeat recorded 4 mentions for Oculis and 1 mentions for MediWound. Oculis' average media sentiment score of 1.24 beat MediWound's score of 0.00 indicating that Oculis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oculis	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Oculis beats MediWound on 10 of the 16 factors compared between the two stocks.

How does MediWound compare to Aclaris Therapeutics?

MediWound (NASDAQ:MDWD) and Aclaris Therapeutics (NASDAQ:ACRS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

MediWound has higher revenue and earnings than Aclaris Therapeutics. Aclaris Therapeutics is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	11.49	-$23.88M	-$2.26	N/A
Aclaris Therapeutics	$8.37M	92.81	-$64.92M	-$0.56	N/A

MediWound has a net margin of -180.30% compared to Aclaris Therapeutics' net margin of -832.58%. Aclaris Therapeutics' return on equity of -55.89% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-180.30%	-67.22%	-31.87%
Aclaris Therapeutics	-832.58%	-55.89%	-38.49%

MediWound presently has a consensus target price of $34.00, suggesting a potential upside of 124.27%. Aclaris Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 106.83%. Given MediWound's higher probable upside, equities analysts plainly believe MediWound is more favorable than Aclaris Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Aclaris Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	3 Strong Buy rating(s)	3.13

46.8% of MediWound shares are owned by institutional investors. Comparatively, 98.3% of Aclaris Therapeutics shares are owned by institutional investors. 9.2% of MediWound shares are owned by insiders. Comparatively, 4.8% of Aclaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

MediWound has a beta of 0.14, indicating that its stock price is 86% less volatile than the broader market. Comparatively, Aclaris Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

In the previous week, MediWound and MediWound both had 1 articles in the media. Aclaris Therapeutics' average media sentiment score of 0.50 beat MediWound's score of 0.00 indicating that Aclaris Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aclaris Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aclaris Therapeutics beats MediWound on 9 of the 16 factors compared between the two stocks.

How does MediWound compare to Candel Therapeutics?

MediWound (NASDAQ:MDWD) and Candel Therapeutics (NASDAQ:CADL) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

Candel Therapeutics has a net margin of 0.00% compared to MediWound's net margin of -180.30%. Candel Therapeutics' return on equity of -60.42% beat MediWound's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-180.30%	-67.22%	-31.87%
Candel Therapeutics	N/A	-60.42%	-41.33%

MediWound presently has a consensus price target of $34.00, suggesting a potential upside of 124.27%. Candel Therapeutics has a consensus price target of $18.00, suggesting a potential upside of 83.11%. Given MediWound's higher possible upside, equities research analysts clearly believe MediWound is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

MediWound has higher revenue and earnings than Candel Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than MediWound, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	11.49	-$23.88M	-$2.26	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A

46.8% of MediWound shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 9.2% of MediWound shares are owned by insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

MediWound has a beta of 0.14, suggesting that its share price is 86% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.52, suggesting that its share price is 152% less volatile than the broader market.

In the previous week, Candel Therapeutics had 8 more articles in the media than MediWound. MarketBeat recorded 9 mentions for Candel Therapeutics and 1 mentions for MediWound. MediWound's average media sentiment score of 0.00 beat Candel Therapeutics' score of -0.07 indicating that MediWound is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Candel Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Summary

MediWound beats Candel Therapeutics on 8 of the 15 factors compared between the two stocks.

Get MediWound News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDWD vs. The Competition

Export

Metric	MediWound	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$194.84M	$3.10B	$7.18B	$12.48B
Dividend Yield	N/A	2.05%	2.66%	6.51%
P/E Ratio	-6.71	20.06	28.02	24.70
Price / Sales	11.49	357.03	535.36	97.93
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	4.46	4.32	10.96	6.46
Net Income	-$23.88M	$64.45M	$3.57B	$337.01M
7 Day Performance	-0.20%	2.97%	2.12%	1.69%
1 Month Performance	6.91%	6.83%	5.25%	3.81%
1 Year Performance	-22.14%	29.07%	33.29%	23.90%

MediWound Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDWD MediWound	2.4367 of 5 stars	$15.16 flat	$34.00 +124.3%	-22.1%	$194.84M	$16.96M	N/A	80	News Coverage Positive News
CLYM Climb Bio	2.6562 of 5 stars	$12.30 +1.0%	$21.73 +76.6%	+907.8%	$697.46M	N/A	N/A	9
CRMD CorMedix	3.5112 of 5 stars	$8.60 -2.5%	$15.00 +74.4%	-24.8%	$691.95M	$311.71M	4.04	30	Gap Down
OCS Oculis	3.5462 of 5 stars	$11.72 +0.4%	$38.33 +227.1%	-25.5%	$676.68M	$1.45M	N/A	2	News Coverage Short Interest Increase
ACRS Aclaris Therapeutics	3.1788 of 5 stars	$4.92 +1.7%	$11.50 +133.7%	+284.8%	$675.97M	$7.83M	N/A	100	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDWD) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MediWound (MDWD) Competitors